Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use

Medivation senior marketing director Gregg Bernier

Astellas and Medivation ($MDVN) haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--have appeared in journals such as Patient Resource; it also includes some direct relationship marketing.

However, while we likely won't see Xtandi-branded TV ads, an unbranded prostate cancer education campaign coming later this year could include a bigger push. Gregg Bernier, senior director of marketing at Medivation, couldn't offer details, saying the unbranded work is still in the planning stages.

Xtandi's pre-chemo approval made waves in the prostate cancer world, giving Johnson & Johnson's ($JNJ) market-leading Zytiga its first head-to-head competition in that indication. Serious competition at that. Xtandi sales for Q1 were $357 million, with the number of scripts written up by 4,000 to 5,000 over the previous quarter. Drug sales for Xtandi topped the $1 billion mark last year, with some analysts saying Xtandi will overtake Zytiga next year.

Zytiga had a jump on marketing the pre-chemo indication, which it won in December 2012. Last year, Astellas and Medivation both bumped up their Xtandi sales forces to about 90 from 60 to address the expanded pre-chemo use with visits to urology practices beyond those that offer chemotherapy.

Bernier agreed that Zytiga is Xtandi's top competitor in the space, but added that others--such as Dendreon's Provenge and generic bicalutamide, as well as others in development--add up to a very competitive space. It's also a growing and potentially lucrative space with estimates of the prostate cancer market doubling to $9.1 billion by 2021, according to Decision Resources. Xtandi is expected to draw sales of $2.2 billion by then.

Special Reports: Top 15 Drug Launch Superstars - Xtandi - Zytiga

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.